Efficacy of newer generation antipsychotics in the treatment of schizophrenia

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 1, 2003, Pages 9-26

  Tandon, R ^a   Jibson, M D ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Atypical antipsychotic; Comparison; Efficacy; Schizophrenia; Tolerability

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRAZODONE; ZIPRASIDONE;

AKATHISIA; AKINESIA; ANTICHOLINERGIC EFFECT; ARTICLE; BLOOD TOXICITY; BRADYKINESIA; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; METHODOLOGY; MOOD DISORDER; NEGATIVE SYNDROME; NEUROPHARMACOLOGY; PARAMETER; PARKINSONISM; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0037214276     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00110-5     Document Type: Article

References (68)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999;1686-1696.
2. Angell M. The pharmaceutical industry: to whom is it responsible? New Engl. J. Med. 342:2000;1902-1904.
3. Arvanitis L.A., Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry. 42:1997;233-246.
4. Beasley C.M. Jr., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
5. Beasley C.M. Jr., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 7:1997;125-137.
6. Bilder R.M. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can. J. Psychiatry. 42:1997;255-264.
7. Blin O., Azorin J.M., Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J. Clin. Psychopharmacol. 16:1996;38-44.
8. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. Psychiatry. 155:1998;499-504.
9. Brecher M., Rak I.W., Melvin K., Jones A.M. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int. J. Psychiatry Clin. Pract. 4:2000;287-292.
10. Brecher M., Geller W. Weight gain with risperidone. J. Clin. Psychopharmacol. 17:1997;435-436.
11. Carpenter W.T. Jr. Phase IV industry-sponsored trials are of little or no value. J. Psychotic Dis. 5:2001;2-4.
12. Casey D.E. Motor and mental aspects of EPS. Int. Clin. Psychopharmacol. 10:1995;105-114.
13. Casey D.E. The relationship of pharmacology to side effects. J. Clin. Psychiatry. 58:(Suppl. 10):1997;55-62.
14. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 158:2001;518-526.
15. Chalmers I. Underreporting research is scientific misconduct. JAMA. 263:1990;1405-1408.
16. Chouinard G., Annable L., Ross-Chouinard A., Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 8:(Suppl. 3):1988;S21-S26.
17. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
18. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl. J. Med. 342:2000;1887-1892.
19. Conley R.R. Phase IV industry-sponsored trials provide useful information. J. Psychotic Dis. 5:2001;4-5.
20. Conley R.R., Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 158:2001;765-774.
21. Copolov D.L., Link C.G., Kowalcyk B. A multicenter, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med. 30:(636):2000;95-105.
22. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 20:1999;491-505.
23. Davidoff F., DeAngelis C.D., Drazen J.M., Hoey J., Højgaard L., Horton R., Kotzin S., Nicholls M.G., Nylenna M., Overbeke A.J., Sox H.C., Van Der Weyden M.B., Wilkes M.S. Sponsorship, authorship, and accountability. JAMA. 286:2001;1232-1234.
24. DeQuardo J.R., Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J. Psychiatric Res. 32:1998;229-242.
25. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 25:1999;721-729.
26. Emsley R.A., Raniwalla J., Bailey P.J., Jones A.M. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 15:2000;121-131.
27. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch. Gen. Psychiatry. 52:1995;173-188.
28. Harvey P.D., Keefe R.S.E. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums. 2:1997;41-55.
29. Hoyberg O.J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr. Scand. 88:1993;395-402.
30. Huttunen M.O., Piepponen T., Rantanen H., Larmo I., Nyholm R., Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr. Scand. 91:1995;271-277.
31. Jakovljevic M., Dossenbach M.R., Friedel P., Schausberger B., Grundy S.L., Hotujac L., Folnegovic-Smalc V., Uglesic B., Tollefson G.D., the Olanzapine HGCH Group. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatr. Danubina. 11:1999;3-11.
32. Jibson M.D., Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32:1998;215-228.
33. Jibson M.D., Tandon R. Treatment of schizophrenia. Psychiatr. Clin. North Am. 7:2000;83-113.
34. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
35. Kane J.M., Woerner M., Lieberman J.A. Tardive dyskinesia: prevalence, incidence and risk factors. J. Clin. Psychopharmacol. 8:(Suppl.):1988;S52-S56.
36. Kane J.M. Pharmacologic treatment of schizophrenia. Biol. Psychiatry. 46:1999;1396-1408.
37. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
38. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19:1999;57-61.
39. LeLorier J., Gregoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies between meta-analyses and subsequent large randomized controlled trials. New Engl. J. Med. 337:1997;536-542.
40. Maixner S.M., Mellow A.M., Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J. Clin. Psychiatry. 60:(Suppl. 8):1999;29-41.
41. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
42. Meltzer H.Y. New drugs for the treatment of schizophrenia. Psychiatr. Clin. North Am. 16:1993;365-385.
43. Miller D.D., Tandon R. The biology and pathophysiology of negative symptoms. Keefe R., McEvoy J. Negative Symptoms of Schizophrenia. 2000;163-186 American Psychiatric Association Press, Washington, DC.
44. Min S.K., Rhee C.S., Kim C.E., Kang D.Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med. J. 34:1993;179-190.
45. Mullen J., Jibson M.D., Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23:2001;1839-1854.
46. Nair N.P. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. J. Clin. Psychopharmacol. 18:1998;103-110.
47. Olanzapine US Prescribing Information, 2000. Eli Lilly and Company.
48. Owens D.G. Extrapyramidal side effects and tolerability of risperidone: a review. J. Clin. Psychiatry. 55:(5, Suppl.):1994;29-35.
49. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry. 166:1995;712-726. (discussion 727-733).
50. Peuskens J., Link C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 96:1997;265-273.
51. Peuskens J., Bech P., Moller H.J., Bale R., Fleurot O., Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 88:1999;107-117.
52. Richards M., Touchon J., Ledesert B., Ritchie K. Mild extrapyramidal signs and functional impairment in aging. Int. J. Geriatric Psychiatry. 17:2002;150-153.
53. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry. 48:1991;618-624.
54. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry. 54:1997;549-557.
55. Srisurapanont M., Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. J. Med. Assoc. Thai. 82:1999;341-346.
56. Strauss M.E., Reynolds K.S., Jayaram G., Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 3:1990;127-129.
57. Tandon R., Ribeiro S.C., DeQuardo J.R., Goldman R.S., Goodson J., Greden J.F. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol. Psychiatry. 34:1993;495-497.
58. Tandon R., Goldman R.S., DeQuardo J.R., Goldman M., Perez M., Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J. Psychiatr. Res. 27:1993;341-347.
59. Tandon R., Jibson M., Taylor S.F., DeQuardo J.R. The pathophysiology of positive and negative symptoms in schizophrenia. Shriqui C., Nasrallah H.A. Contemporary Issues in the Treatment of Schizophrenia. 1995;109-124 American Psychiatric Press, Washington, DC.
60. Tandon R., Harrigan E., Zorn S.H. Ziprasidone: a novel antipsychotic with unique pharmacological and therapeutic potential. J. Serotonin Res. 4:1997;159-177.
61. Tandon R. Antipsychotic agents. Klein D.F., Rowland L.P. Current Psychotherapeutic Drugs. 1998;120-154 Brunner/Mazel, New York.
62. Tandon R., Milner K., Jibson M.D. Antipsychotics from theory to practice: integrating clinical and basic data. J. Clin. Psychiatry. 60:(Suppl. 8):1999;21-28.
63. Tandon R. Industry-sponsored Phase IV clinical trials: promises and pitfalls, information and misinformation. J. Psychotic Dis. 5:2001;14-15.
64. Thompson S.G., Pocock S.J. Can meta-analyses be trusted? Lancet. 338:1991;1127-1130.
65. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
66. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C. Jr., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17:1997;407-418.
67. Tune L.E., Strauss M.E., Lew M.F., Breitlinger E., Coyle J.T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry. 139:1982;1460-1462.
68. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch. Gen. Psychiatry. 31:1974;67-72.